British Columbia has over 20 Prostate Cancer Support Groups meet once a month. This group is focused on providing help to Chinese-speaking men, but everyone is welcome. We speak Mandarin, Cantonese and English. We meet on the second Thursday of every month from 7:00pm to 9:00pm at the Richmond Public Library (2/F Brighouse Main Branch, 7700 Minoru Gate, Richmond, BC V6Y 1R8). Please register online at The Richmond Public Library website. Join us for the professional presentation and talk to other men and family members who have been dealing with prostate cancer for weeks, months or even years.

If you want to chat with a survivor one on one, you may drop in our walking club. The Richmond Blue Walkers walk on every Tuesdays and Thursdays 9-11am, 5-10 km along the beautiful river dykes and parks in Richmond (Walk in the Richmond Shopping Centre during the raining days or cold seasons). Click here for the schedule or contact Daniel Leung at 604-836-6423 for the locations and meeting places.

The Prostate Cancer Foundation of BC accepts donation online, please go tohttp://prostatecancerbc.ca/ 捐款請到前列腺癌基金會http://prostatecancerbc.ca/

支援小組乃義工組織我們講普通話廣東話和英語幫助您了解良性前列腺疾病與前列腺癌的病徵預防治療康復與最新醫療硏究等資訊我們每月一次第二個星期四從下午7:009:00在列治文公共圖書館二樓市中心公眾泳池對面舉辦免費聚會邀請中英專業人仕主辦醫療與健康講座交流經驗與分享感受報名請到圖書館網站 或致電604-231-6413 (英語) 604-231-6462(中文)報名

列治文前列腺癌友步行團 每週二和週四早上九時至十一時沿著美麗的河堤和公園散步在下雨天或寒冷季節步行於列治文購物中心)。查詢活動更新請打電話604-836-6423 (Daniel)

This blog is provided as a public service. Any persons using the information or documents provided on the blog do so at their own risk. Reference: Oncology Guide to Reliable Websites

Friday, October 30, 2015

'Milestone' prostate cancer drug “里程碑”前列腺癌藥物

  • 29 October 2015
  •  
  • From the sectionHealth

Prostate cancer cellImage copyrightSPL

The first drug that targets precise genetic mutations in prostate cancer has been shown to be effective in a "milestone" trial by UK scientists.
The study, at the Institute of Cancer Research in London, took place on 49 men with untreatable cancer.
The drug, olaparib, had low overall success, but slowed tumour growth in 88% of patients with specific DNA mutations.
Cancer Research UK said the trial was exciting.
The future of cancer medicine is treating cancers by their mutated DNA rather than what part of the body they are in.
The breast cancer drug Herceptin is already used only in patients with specific mutations. Olaparib targets mutations that change the way DNA is repaired.

DNAImage copyrightThinkstock

The trial results, published in the New England Journal of Medicine, showed the drug worked in 14 out of 16 men with such mutations.
Levels of Prostate Specific Antigen, which is produced by tumours, was more than halved and there were also significant falls in the number of prostate cancer cells detected in the blood and in the size of secondary tumours.
Patients responded to the drug for between six months and nearly a year and a half.
One of the researchers, Dr Joaquin Mateo, told the BBC News website: "It is very promising.
"Those entering the trial had an expected survival of 10 to 12 months and we have many patients on the drug for longer than a year."

Prostate cancerImage copyrightSPL
Image captionProstate cancer can spread to bone (in green)

Prostate cancer is the fifth most deadly type of cancer in men.
However, a larger clinical trial is needed before doctors can say if the drug extends life expectancy.
Dr Mateo added: "This is the first drug that targets specific genetically defined populations and we are going to see more and more of these coming in the next few years."
The advantage of targeted drugs is they can be given only to those patients who will respond, which both saves money and spares patients unnecessary side effects.
Some of the patients in the study were born with mutated DNA repair genes while in others the mutation developed inside the tumour.

'Significant step'

Professor Johann de Bono, the head of drug development at the Institute of Cancer Research said: "Our trial marks a significant step forward in the treatment of prostate cancer.
"I hope it won't be long before we are using olaparib in the clinic to treat prostate cancer."
However, the drugs watchdog in England - the National Institute for Health and Care Excellence - has already rejected olaparib for ovarian cancer on grounds - at £4,000 a month - of cost.
Cancer Research UK's Dr Aine McCarthy added: "This trial is exciting because it could offer a new way to treat prostate cancer by targeting genetic mistakes in cancers that have spread.
"The hope is that this approach could help save many more lives in the future."
Follow James on Twitter.

No comments:

Post a Comment